Blog

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Photo tsaken from Samarpana Chakraborty/X

Aug 10, 2024, 13:03

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Samarpana Chakraborty, Postdoctoral Researcher at Albert Einstein College of Medicine shared a post by Aditi Shastri, Associate Professor at Albert Einstein College of Medicine on X:

“Thrilled to share my postdoctoral work on STAT3 degraders in Venetoclax resistant AML. Grateful to Shastri lab and Aditi Shastri for giving me the opportunity to work on this fantastic project. ”

Quoting Aditi Shastri’s post:

“A new manuscript from shastri lab just dropped “A STAT3 Degrader Demonstrates Preclinical Efficacy in Venetoclax Resistant AML”. Congratulations to first author Samarpana Chakraborty and a huge thanks to amazing collabs and Kymera Therapeutics, EinsteinSCI, and Montefiore Health System.”

Source: Samarpana Chakraborty/X and Aditi Shastri/X

Aditi Shastri Albert Einstein College of Medicine cancer EinsteinSCI Kymera Therapeutics Montefiore Health System OncoDaily Oncology Samarpana Chakraborty

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer